Lobbying client

AV THERAPEUTICS INC.

Developer of cancer therapeutics and immunotherapeutic vaccines.

The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 2 of its records are shown together here.

Filings
27
Filed by
2
Reported in-house
—
Reported by firms
—

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2017 to 2023

Filings

27 filings, newest first.
Filing Filed by Amount
2nd Quarter - Termination (No Activity)
2nd Quarter 2023
THE VOGEL GROUP — reported
1st Quarter - Report (No Activity)
1st Quarter 2023
THE VOGEL GROUP — reported
4th Quarter - Report (No Activity)
4th Quarter 2022
THE VOGEL GROUP — reported
3rd Quarter - Report (No Activity)
3rd Quarter 2022
THE VOGEL GROUP — reported
2nd Quarter - Report (No Activity)
2nd Quarter 2022
THE VOGEL GROUP — reported
1st Quarter - Report (No Activity)
1st Quarter 2022
THE VOGEL GROUP — reported
4th Quarter - Report (No Activity)
4th Quarter 2021
THE VOGEL GROUP — reported
4th Quarter - Termination (No Activity)
4th Quarter 2021
VAN HEUVELEN STRATEGIES, LLC — reported
Registration
4th Quarter 2021
THE VOGEL GROUP — reported
3rd Quarter - Report (No Activity)
3rd Quarter 2021
VAN HEUVELEN STRATEGIES, LLC — reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
VAN HEUVELEN STRATEGIES, LLC 18 —
THE VOGEL GROUP 7 —

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Health Issues HCR 8
Budget/Appropriations BUD 6

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.